Clinical Trial

Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to test in describe participant population. The main questions it aims to answer are: 1. evaluate the efficacy and safety of tislelizumab combined with APF sequential surgery or radical concurrent chemoradiotherapy in the treatment of locally advanced head and neck tumors. 2. the exploration of efficacy-related immune microenvironment genes Participants will receive tislelizumab combined with APF sequential surgery or radical concurrent chemoradiotherapy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-02-24; most recent amendment 2025-08-29.
Trial Details
NCT Number NCT05758389
Lead Sponsor The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions Head and Neck Tumors
Enrollment 29 participants
Start Date 2022-04-01
Primary Completion 2025-08-07 (estimated)
Study Completion 2025-12-07 (estimated)
Updated on ClinicalTrials.gov 2025-09-05